Foundation establishes Gerald E. McGinnis Fellowship in Sleep Medicine to advance education
 |
Murrysville, PA, Oct. 4, 2006 – Respironics, Inc., (NASDAQ: RESP), a leader in the global sleep and respiratory markets, held a company celebration today at its U.S. headquarters, marking its 30th year of making medical devices that help people sleep and breathe easier. The occasion celebrated another record achievement in fiscal year 2006: surpassing $1 billion in revenues. The Company also announced a new fellowship program through the Respironics Sleep and Respiratory Research Foundation.
At the heart of the event, which took place on Respironics' 32-acre campus in Murrysville, Pennsylvania, near Pittsburgh, was a tribute to the many contributions of the Company's founder and chairman, Gerald E. "Jerry" McGinnis in sleep and respiratory care. The ceremony included remarks by dignitaries and recollections by longtime friends, colleagues and leaders in the medical community who were instrumental in Mr. McGinnis' early efforts to bring innovative devices, such as anesthesia masks and the first commercial continuous positive airway pressure (CPAP) device for treating obstructive sleep apnea, to the marketplace.
 |
"Today is a proud day in our Company's history," said John Miclot, Respironics' president and CEO, before the packed crowd of public officials, business and community leaders, and about 900 of its local employees. "We are honored to have you with us to help us celebrate another milestone and to thank you for your incredible show of support over the years. We look forward to an exciting and bright future as we take on our next decade of growth and innovation."
Respironics Sleep and Respiratory Research Foundation reaffirmed its commitment to research and education through the creation of the Gerald E. McGinnis Fellowship in Sleep Medicine in the Division of Pulmonary, Allergy and Critical Care Medicine in the University of Pittsburgh School of Medicine. The Foundation pledged $325,000 over the next five years to fund the new program, which trains academic physicians and provides a one-year clinical experience in sleep medicine. "This is another way we're giving back to the community," Miclot added. "In doing so, we're paying homage to our founder and advancing education and research in the field of sleep medicine."
 |
About Respironics
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,700 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.
This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.
© 2006 Respironics, Inc. and its affiliates. All rights reserved.
My Respironics | Suppliers | Clinicians | Media Resource Library | Contact Us
All Rights Reserved | Privacy Notice | Terms & Conditions | Site Map